Advertisements


Flex Pharma Shares Plunge After Biotech Ends 2 Clinical Trials, Announces 60% Workforce Cut

Flex Pharma Inc (NASDAQ: FLKS) shares are slumping on above-average volume Wednesday following a release from the company announcing the scrapping of two clinical trials and the explo read more.....»»

Category: blogSource: benzingaJun 13th, 2018

Why Gemphire Is Tuesday’s Big Biotech Loser

Gemphire shares were more than halved on Tuesday after the company provided an update in regards to the clinical hold on gemcabene with respect to clinical trials of longer than six months in........»»

Category: blogSource: 247wallstAug 7th, 2018

Flex Pharma Down on Workforce Reduction, Ends Phase II Study

Flex Pharma (FLKS) announced that the company is ending the phase II studies for its pipeline candidate FLX-787 in two indications. The company also plans to lower its workforce by about 60%. F.....»»

Category: smallbizSource: nytJun 14th, 2018

Flex Pharma to end Phase 2 trials, explore alternatives, cut workforce

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 13th, 2018

Akari Announces First Quarter 2018 Financial Results and Update on its Growing Pipeline of Phase II and Phase III Clinical Trials

Opened three clinical trials in 2018 Trials in which complement dysregulation is the primary disease driver CAPSTONE, the Phase III trial in naïve paroxysmal nocturnal hemoglobinuria (PNH), in which patient treatment has commenced Phase II U.S. trial f.....»»

Category: earningsSource: benzingaAug 17th, 2018

Mixed Reviews For Allakos As Sell-Side Starts Coverage Of Biotech

Allakos Inc (NASDAQ: ALLK), a clinical-stage biotech company developing treatment for various eosinophil and mast-cell related diseases, offered 7.13 million shares in a.....»»

Category: blogSource: benzingaAug 13th, 2018

Benzinga"s Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold

Here's a rou.....»»

Category: earningsSource: benzingaJul 26th, 2018

Benzinga"s Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on July 25) read more.....»»

Category: blogSource: benzingaJul 26th, 2018

Advaxis shares rise 68% after FDA lifts clinical hold on its drug trial

Shares of the biotech company Advaxis Inc. surged 68% in premarket trade on Friday after the Food and Drug Administration lifted a clinical hold on the company's phase 1/2 study for a cancer drug combination. The clinical hol.....»»

Category: topSource: marketwatchJul 13th, 2018

Biotech Analysis Central Pharma News: Catabasis Nears Phase 3 Start, Regulus Slashes Workforce, Cytori"s Mixed ED Data

Biotech Analysis Central Pharma News: Catabasis Nears Phase 3 Start, Regulus Slashes Workforce, Cytori"s Mixed ED Data.....»»

Category: topSource: seekingalphaJul 10th, 2018

The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Biotech stocks held their ground in a holiday-shortened week amid a drought of market-moving catalysts. Looking ahead, the following are catalytic events for biotech investors to watch.  read more.....»»

Category: blogSource: benzingaJul 8th, 2018

Compugen shares surge 12% premarket after FDA lifts clinical hold on cancer treatment

Compugen Ltd. shares climbed 12% in premarket trade Monday, after the Israeli biotech said the U.S. Foo.....»»

Category: topSource: marketwatchJul 2nd, 2018

Celgene, Acceleron shares rise on positive late-stage trial results

Celgene Corp. shares rose 2.4% in premarket trade on Friday and Acceleron Pharma Inc. shares rose 19.5% after the companies said a late-stage clinical trial for low-to-intermediate risk myelodysplastic syndromes had positive results. The trial met its.....»»

Category: topSource: marketwatchJun 29th, 2018

Walgreens and CVS Shares Plunge After Amazon Announces Deal to Buy Online Pharmacy PillPack

The move instantly turns Amazon into a major online druggist. Amazon.com is about to wreak havoc in yet another area of retail: drugstores. The company said on Thursday morni.....»»

Category: europeSource: fortuneJun 28th, 2018

UPDATE: Arsanis shares slide 73% on news to discontinue trial of pneumonia treatment

Shares of Arsanis Inc., a clinical-stage biotech, slid 73% in premarket trade Thursday, after the company said it is discontinuing a Phase 2 trial of a treatment for pn.....»»

Category: topSource: marketwatchJun 28th, 2018

Aquinox Pharma shares slide 73% premarket after cystitis drug trial fails to meet main goal

Aquinox Pharmaceuticals Inc. shares slid 73% in premarket trade Wednesday, after the Canadian-based biotech said a trial of a treatment for cystitis and severe bladder.....»»

Category: topSource: marketwatchJun 27th, 2018

Why Infinity Pharma Shares Are Booming

Infinity Pharmaceuticals shares made a healthy gain early on Tuesday after the firm announced a clinical collaboration with Arcus Biosciences......»»

Category: blogSource: 247wallstJun 26th, 2018

UPDATE: Merrimack Pharma shares slide 34% after trial of pancreatic cancer treatment fails to meet main goals

Merrimack Pharmaceuticals Inc. said Monday a midstage trial of a treatment for pancreatic cancer failed to meet its main goals. The clinical.....»»

Category: topSource: marketwatchJun 25th, 2018

Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives

Shares of bluebird bio Inc (NASDAQ: BLUE) — a clinical-stage.....»»

Category: blogSource: benzingaJun 23rd, 2018

Forty Seven Announces Potential Pricing for IPO

Clinical-stage immuno-oncology company Forty Seven intends to price more than 6 million shares so that the entire offering is valued up to more than $123 million......»»

Category: blogSource: 247wallstJun 18th, 2018

Mid-Day Market Update: Pivotal Software Gains Following Q1 Results; Flex Pharma Shares Slide

Midway through trading Wednesday, the Dow traded up 0.08 percent to 25,340.76 while the NASDAQ climbed 0.41 percent to 7,735.18. The S&P also rose, gaining 0.12 percent to 2,790.15. read more.....»»

Category: blogSource: benzingaJun 13th, 2018